Assessment of Marketing Authorization and Bidding Status of Cardiovascular Drugs in Vietnam in 2024
Author(s)
Ngan T. Le1, Thuy Thi Thu Nguyen, MBA, PhD2.
1Quan 10, Viet Nam, 2University of Medicine and Pharmacy at Ho Chi Minh city, Ho Chi Minh, Viet Nam.
1Quan 10, Viet Nam, 2University of Medicine and Pharmacy at Ho Chi Minh city, Ho Chi Minh, Viet Nam.
OBJECTIVES: To assess the current status of registration and bidding of cardiovascular drugs in Vietnam in 2024.
METHODS: A cross-sectional descriptive study utilizing retrospective data on marketing authorization approvals and tendering outcomes for cardiovascular drugs in Vietnam in 2024, obtained from the Drug Administration of Vietnam’s registration database and the Social Health Insurance drug procurement management system.
RESULTS: In 2024, a total of 1,635 marketing authorizations were granted for cardiovascular drugs, covering 107 active pharmaceutical ingredients (APIs). Among these, 53.8% were indicated for hypertension management, 80.8% were domestically manufactured, and 95.3% were oral formulations. Regarding procurement outcomes, 98 out of 107 APIs (91.6%) and 1,521 out of 1,635 brand-name drugs (93.0%) were awarded in tenders. Of the awarded drugs, 51.0% were antihypertensive agents, 56.7% were domestically produced branded drugs, 45.5% were categorized in group 4, and oral administration remained the predominant route at 94.5%. The total awarded quantity reached 2,085.0 million units, with a total procurement value of VND 5,743.1 billion. Antihypertensive agents accounted for the highest volume and value of procurement, at 1,456.3 million units (69.8%) and VND 3,821.2 billion (66.5%), respectively.
CONCLUSIONS: The analysis of the registration and procurement status of cardiovascular drugs in 2024 indicates that most approved drugs were domestically manufactured and orally administered. The high proportion of awarded drugs (93.0%) relative to the total number of registered drugs reflects a relatively strong alignment between the registered product list and the national drug supply capacity through public procurement.
METHODS: A cross-sectional descriptive study utilizing retrospective data on marketing authorization approvals and tendering outcomes for cardiovascular drugs in Vietnam in 2024, obtained from the Drug Administration of Vietnam’s registration database and the Social Health Insurance drug procurement management system.
RESULTS: In 2024, a total of 1,635 marketing authorizations were granted for cardiovascular drugs, covering 107 active pharmaceutical ingredients (APIs). Among these, 53.8% were indicated for hypertension management, 80.8% were domestically manufactured, and 95.3% were oral formulations. Regarding procurement outcomes, 98 out of 107 APIs (91.6%) and 1,521 out of 1,635 brand-name drugs (93.0%) were awarded in tenders. Of the awarded drugs, 51.0% were antihypertensive agents, 56.7% were domestically produced branded drugs, 45.5% were categorized in group 4, and oral administration remained the predominant route at 94.5%. The total awarded quantity reached 2,085.0 million units, with a total procurement value of VND 5,743.1 billion. Antihypertensive agents accounted for the highest volume and value of procurement, at 1,456.3 million units (69.8%) and VND 3,821.2 billion (66.5%), respectively.
CONCLUSIONS: The analysis of the registration and procurement status of cardiovascular drugs in 2024 indicates that most approved drugs were domestically manufactured and orally administered. The high proportion of awarded drugs (93.0%) relative to the total number of registered drugs reflects a relatively strong alignment between the registered product list and the national drug supply capacity through public procurement.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
HPR31
Topic
Health Policy & Regulatory
Topic Subcategory
Approval & Labeling, Procurement Systems
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory)